Henlius

Biotechnology, Milmont Dr Ste 107c, shanghai, , 94538, California, 48860, United States, 1001-5000 Employees

Phone Number: +15*********

Who is HENLIUS

Henlius (2696.HK) is a global biopharmaceutical company with the vision to offer high-quality, affordable, and innovative biologic medicines for patients worldwide with a focus on oncolog...

Get Full Access

Headquarters: 48860 Milmont Dr Ste 107c, shanghai, California, 94538, United States
Date Founded: 2010
Employees: 1001-5000
Revenue: $5 Million to $10 Million
Active Tech Stack: See technologies

Industry: Biotechnology

SIC Code: 8731 | NAICS Code: 541715 | Show More

Does something look wrong? Fix it. | View contact records from HENLIUS

Henlius Org Chart and Mapping

Employees

Leon T

Senior Director of Business Development, in-Licensing

Email
Phone

See Full Org Chart

View Email Formats for Henlius

You are signed out

Join Now

Free credits every month

Frequently Asked Questions Regarding Henlius

Answer: Henlius's headquarters are located at Milmont Dr Ste 107c, shanghai, , 94538, California, 48860, United States

Answer: Henlius (2696.HK) is a global biopharmaceutical company with the vision to offer high-quality, affordable, and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases, and ophthalmic diseases. Up to date, 5 products have been launched in China, 2 has been approved for marketing in overseas markets, 19 indications are approved worldwide, and 3 marketing applications have been accepted for review in China, the U.S. and EU, respectively. Since its inception in 2010, Henlius has built an integrated biopharmaceutical platform with core capabilities of high-efficiency and innovation embedded throughout the whole product life cycle including R&D, manufacturing and commercialization. It has established global innovation center and Shanghai-based manufacturing facilities in line with global Good Manufacturing Practice (GMP), including Xuhui Plant certificated by China and the EU GMP and Songjiang First Plant certificated by China GMP. Henlius has pro-actively built a diversified and high-quality product pipeline covering over 20 innovative monoclonal antibodies (mAbs) and has continued to explore immuno-oncology combination therapies with proprietary HANSIZHUANG (anti-PD-1 mAb) as backbone. Apart from the launched products HANLIKANG (rituximab), the first China-developed biosimilar, HANQUYOU (trastuzumab for injection, trade name in Europe: Zercepac; trade names in Australia: Tuzucip and Trastucip, the first China-developed mAb biosimilar approved both in China and Europe, HANDAYUAN (adalimumab) and HANBEITAI (bevacizumab), HANSIZHUANG has been approved by the NMPA for the treatment of MSI-H solid tumors, sqNSCLC, ES-SCLC, and ESCC, making it the worlds first anti-PD-1 mAb for the first-line treatment of SCLC. Its NDA for the treatment of nsNSCLC is under review. What's more, Henlius has conduct over 30 clinical studies for 16 products globally, expanding its presence in major markets as well as emerging markets.